HTBX Heat Biologics Inc.

0.71
-0.03  -3%
Previous Close 0.74
Open 0.74
Price To Book 0.91
Market Cap 24,200,239
Shares 34,065,652
Volume 99,313
Short Ratio
Av. Daily Volume 358,033

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 additional data due 4Q 2019.
HS-110 and nivolumab (Opdivo)
Non-small cell lung cancer (NSCLC)
Phase 2 trial did not meet primary endpoint - November 30, 2016.
HS-410
Bladder cancer
Phase 1b data released December 6, 2016.
HS-110
Non-small cell lung cancer (NSCLC)

Latest News

  1. HTBX: INDs To Be Filed Soon
  2. Heat Biologics Announces Promising Interim Phase 2 Lung Cancer Data Suggesting that HS-110 Plus Nivolumab May Restore Clinical Benefit After Checkpoint Inhibitor Treatment Failure
  3. Is Heat Biologics, Inc.'s (NASDAQ:HTBX) CEO Overpaid Relative To Its Peers?
  4. Heat Biologics to Present at the 20th Annual B. Riley FBR Institutional Investor Conference
  5. Heat Biologics Reports First Quarter 2019 Results and Provides Corporate Update
  6. Heat Biologics Lead Director to Present at the ChinaBio 2019 Conference in Shanghai
  7. Heat Biologics CEO to Present at the ThinkEquity Conference in New York City
  8. HTBX: 2018 Financial & Operational Results
  9. Heat Biologics Delivers Poster Presentation at the AACR Annual Meeting 2019
  10. Heat Biologics Reports 2018 Results and Provides Corporate Update
  11. Heat Biologics to Present at the Chinese Society for Clinical Oncology Conference on Immunotherapy
  12. HTBX: HS-110 Interim Update
  13. Heat Biologics Lead Director to Chair Oncology Roundtable Discussion at WuXi Healthcare Forum in Shanghai
  14. Heat Biologics Presents Interim Phase 2 Lung Cancer Data on HS-110 + Nivolumab at ASCO-SITC Clinical Immuno-Oncology Symposium
  15. These Four Healthcare Stocks Are Heating Up On Tuesday
  16. What Type Of Shareholder Owns Heat Biologics, Inc.’s (NASDAQ:HTBX)?
  17. UPDATE: Heat Biologics Doses First Patient in New Cohort of its Expanded Phase 2 Trial of HS-110 in Combination with Merck's KEYTRUDA(R) in Non-Small Cell Lung Cancer Trial
  18. Heat Biologics Doses First Patient in New Cohort of its Expanded Phase 2 Trial of HS-110 in Combination with Merck's KEYTRUDA(R) in Non-Small Cell Lung Cancer Trial
  19. The Daily Biotech Pulse: Cancer Genetics Prices Offering, DiaMedica Delists From Canadian Exchange, Medigus CEO Quits
  20. Heat Biologics Provides Clinical and Business Update